{"id":"proair-digihaler","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nervousness"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL714","moleculeType":"Small molecule","molecularWeight":"239.31"},"_dailymed":{"setId":"667ce3ec-5217-4b10-b712-f3e54fbbf087","title":"PROAIR DIGIHALER (ALBUTEROL SULFATE) POWDER, METERED PROAIR DIGIHALER (ALBUTEROL SULFATE) INHALANT [TEVA RESPIRATORY, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ProAir Digihaler is a metered-dose inhaler (MDI) containing albuterol, a short-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing rapid bronchodilation. The device incorporates digital connectivity to track inhaler use, provide feedback on proper technique, and monitor medication adherence. This combination of a proven bronchodilator with digital health monitoring aims to improve patient outcomes and medication compliance.","oneSentence":"ProAir Digihaler is a digital inhaler device that delivers albuterol (salbutamol) to relieve acute bronchospasm and airway obstruction in asthma and COPD patients.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:06:08.632Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute relief of bronchospasm in asthma"},{"name":"Acute relief of bronchospasm in chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT06473779","phase":"PHASE3","title":"Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":"Severe Asthma","enrollment":326},{"nctId":"NCT01851642","phase":"","title":"Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs","status":"RECRUITING","sponsor":"University of Florida","startDate":"2007-08-09","conditions":"Alpha-1 Antitrypsin Deficiency, AAT Deficiency, AATD","enrollment":220},{"nctId":"NCT04901715","phase":"EARLY_PHASE1","title":"Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2021-06-10","conditions":"Primary Ciliary Dyskinesia","enrollment":27},{"nctId":"NCT04997304","phase":"PHASE4","title":"Teva Asthma Predictive Analytics Study","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2021-07-09","conditions":"Asthma","enrollment":100},{"nctId":"NCT04821869","phase":"","title":"ProAir Digihaler in COPD Disease Management: A Real World Study","status":"COMPLETED","sponsor":"Pulmonary Research Institute of Southeast Michigan","startDate":"2021-05-10","conditions":"COPD, COPD Exacerbation Acute","enrollment":27},{"nctId":"NCT02797275","phase":"PHASE4","title":"Secondhand Smoke Respiratory Health Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2016-06-06","conditions":"Secondhand Smoke, Air Trapping, Tobacco","enrollment":107},{"nctId":"NCT04912596","phase":"NA","title":"Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma","status":"RECRUITING","sponsor":"Intech Biopharm Ltd.","startDate":"2022-08-15","conditions":"Mild Asthma","enrollment":148},{"nctId":"NCT00739297","phase":"PHASE1","title":"The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-07","conditions":"Chronic Asthma","enrollment":68},{"nctId":"NCT04803734","phase":"NA","title":"Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108 mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90 mcg Per Actuation in Healthy Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2021-03-19","conditions":"Healthy","enrollment":60},{"nctId":"NCT05300087","phase":"NA","title":"Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90mcg Per Actuation in Healthy Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2022-02-24","conditions":"Healthy","enrollment":60},{"nctId":"NCT05241288","phase":"NA","title":"Digihaler in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":54},{"nctId":"NCT04896645","phase":"NA","title":"Albuterol Integrated Adherence Monitoring in Children With Asthma","status":"COMPLETED","sponsor":"Children's Hospital Los Angeles","startDate":"2021-06-01","conditions":"Asthma in Children","enrollment":21},{"nctId":"NCT00530062","phase":"PHASE4","title":"Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2007-07-25","conditions":"Asthma","enrollment":49},{"nctId":"NCT00308685","phase":"PHASE3","title":"Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2006-06-10","conditions":"Asthma","enrollment":95},{"nctId":"NCT01056159","phase":"PHASE1","title":"A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-01","conditions":"Asthma","enrollment":47},{"nctId":"NCT01899144","phase":"PHASE2","title":"Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-07","conditions":"Asthma","enrollment":61},{"nctId":"NCT00054964","phase":"PHASE2","title":"Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Patients With Poor Inhaler Technique","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2003-03-31","conditions":"Asthma","enrollment":14},{"nctId":"NCT00577655","phase":"PHASE3","title":"Albuterol HFA MDI in Pediatric Participants With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2007-08","conditions":"Asthma","enrollment":103},{"nctId":"NCT03256695","phase":"PHASE3","title":"Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2017-09-28","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":405},{"nctId":"NCT02126839","phase":"PHASE3","title":"A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-05","conditions":"Asthma","enrollment":186},{"nctId":"NCT01058863","phase":"PHASE2","title":"A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-02","conditions":"Asthma","enrollment":72},{"nctId":"NCT02513160","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-09-30","conditions":"Persistent Asthma","enrollment":713},{"nctId":"NCT02175771","phase":"PHASE3","title":"Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"Persistent Asthma","enrollment":758},{"nctId":"NCT04207840","phase":"PHASE4","title":"Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals","status":"COMPLETED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2019-12-09","conditions":"Pharmacokinetics, Epinephrine, Albuterol","enrollment":28},{"nctId":"NCT03528577","phase":"PHASE3","title":"A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2018-09-22","conditions":"Asthma","enrollment":128},{"nctId":"NCT02584257","phase":"PHASE3","title":"Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma","status":"COMPLETED","sponsor":"Lupin, Inc.","startDate":"2016-04","conditions":"Mild Persistent Asthma","enrollment":217},{"nctId":"NCT02478398","phase":"PHASE3","title":"Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-20","conditions":"Rhinitis, Allergic, Seasonal","enrollment":1025},{"nctId":"NCT02447250","phase":"PHASE4","title":"Preterm Infant Inhaled Albuterol Dosing","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2013-10-24","conditions":"Bronchopulmonary Dysplasia, Very Low Birth Weight","enrollment":14},{"nctId":"NCT02885636","phase":"PHASE3","title":"Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2016-09","conditions":"Congestive Heart Failure, Heart Failure, Left-Sided, Left-Sided Heart Failure","enrollment":30},{"nctId":"NCT00394329","phase":"PHASE3","title":"(CARE Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2006-11","conditions":"Asthma","enrollment":288},{"nctId":"NCT03549897","phase":"PHASE3","title":"Bronchoprovocation Study to Evaluate the Pharmacodynamics of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base","status":"UNKNOWN","sponsor":"Amneal Ireland Limited","startDate":"2018-03-16","conditions":"Asthma","enrollment":100},{"nctId":"NCT03480997","phase":"PHASE1","title":"Acute Bronchodilator Effect of Inhaled Albuterol Sulfate and Ipratropium Bromide in Patients With Stable COPD","status":"COMPLETED","sponsor":"Pneuma Respiratory, Inc","startDate":"2016-12-27","conditions":"COPD","enrollment":46},{"nctId":"NCT00588406","phase":"PHASE3","title":"Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2007-09","conditions":"Asthma","enrollment":95},{"nctId":"NCT01698320","phase":"PHASE3","title":"Safety Study of Albuterol Spiromax® in Subjects With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-10","conditions":"Asthma","enrollment":364},{"nctId":"NCT01424813","phase":"PHASE3","title":"A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-12","conditions":"Asthma","enrollment":158},{"nctId":"NCT01747629","phase":"PHASE3","title":"Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-12","conditions":"Asthma","enrollment":160},{"nctId":"NCT01791972","phase":"PHASE3","title":"Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-03","conditions":"Exercise-Induced Bronchoconstriction (EIB)","enrollment":38},{"nctId":"NCT01857323","phase":"PHASE3","title":"Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-05","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":317},{"nctId":"NCT01218009","phase":"PHASE3","title":"A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-10","conditions":"Asthma","enrollment":331},{"nctId":"NCT00623688","phase":"NA","title":"Effectiveness and Cost Study Comparing Two Ways to Deliver Albuterol for the Treatment of Asthma in the Hospital","status":"COMPLETED","sponsor":"Akron Children's Hospital","startDate":"2008-02","conditions":"Status Asthmaticus","enrollment":11},{"nctId":"NCT01844401","phase":"PHASE1","title":"Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-04","conditions":"Asthma","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Digihaler Device"],"phase":"marketed","status":"active","brandName":"ProAir Digihaler","genericName":"ProAir Digihaler","companyName":"Pulmonary Research Institute of Southeast Michigan","companyId":"pulmonary-research-institute-of-southeast-michigan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ProAir Digihaler is a digital inhaler device that delivers albuterol (salbutamol) to relieve acute bronchospasm and airway obstruction in asthma and COPD patients. Used for Acute relief of bronchospasm in asthma, Acute relief of bronchospasm in chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}